Search results
Showing 51 to 71 of 71 results for psoriasis
Tofacitinib for treating juvenile idiopathic arthritis (TA735)
Evidence-based recommendations on tofacitinib for treating juvenile idiopathic arthritis.
Find out more about NICE technology appraisals advisory committee D members
Discontinued [GID-TAG412]
Secukinumab for treating non-radiographic axial spondyloarthritis (TA719)
Evidence-based recommendations on secukinumab (Cosentyx) for treating non-radiographic axial spondyloarthritis in adults.
Summary of the evidence on remsima (infliximab biosimilar) for subcutaneous injection for managing Crohn’s disease and ulcerative colitis
treatment of malignant pleural mesothelioma (2) 23 November 2007 TA103 Psoriasis - efalizumab and etanercept 27 January 2006 TA104...
guidance Certolizumab pegol for treating moderate to severe plaque psoriasis Number TA574 Date issued April 2019 Other details
from guidance Tildrakizumab for treating moderate to severe plaque psoriasis Number TA575 Date issued April 2019 Other details
Summary of the evidence on infliximab for treating refractory extrapulmonary sarcoidosis to inform local NHS planning and decision-making
This quality standard covers interventions to improve the uptake of HIV testing among people who may have undiagnosed HIV. It focuses on increasing testing to reduce undiagnosed infection in people at increased risk of exposure. It describes high-quality care in priority areas for improvement.
View quality statements for QS157Show all sections
Sections for QS157
- Quality statements
- Quality statement 1: Hospitals in areas of high and extremely high HIV prevalence
- Quality statement 2: General practice in areas of high and extremely high HIV prevalence
- Quality statement 3: HIV indicator conditions
- Quality statement 4: Regular HIV testing
- Quality statement 5: People who may have been exposed to HIV
- Update information
- About this quality standard
Lay representatives David Chandler David is chief executive of the Psoriasis and Psoriatic Arthritis Alliance (PAPAA), a UK patient...
Evidence-based recommendations on baricitinib (Olumiant) for treating severe alopecia areata in adults.
Spesolimab for preventing generalised pustular psoriasis flares [ID6216]
In development [GID-TA11189] Expected publication date: TBC
Apremilast for treating moderate to severe plaque psoriasis (TA368)
This guidance has been updated and replaced by NICE technology appraisal guidance 419. Adalimumab for treating moderate to severe hidradenitis suppurativa (TA392)
Evidence-based recommendations on adalimumab (Humira) for treating active moderate to severe hidradenitis suppurativa in adults whose disease has not responded to conventional systemic therapy.
Evidence-based recommendations on apremilast (Otezla) for treating active psoriatic arthritis.
Secukinumab for treating moderate to severe hidradenitis suppurativa (TA935)
Evidence-based recommendations on secukinumab (Cosentyx) for active moderate to severe hidradenitis suppurativa (acne inversa) in adults.
TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (TA383)
Evidence-based recommendations on adalimumab (Humira), certolizumab pegol (Cimzia), etanercept (Enbrel), golimumab (Simponi) and infliximab (Remicade, Remsima, Inflectra). These drugs are for people with severe active ankylosing spondylitis or severe non-radiographic axial spondyloarthritis who have tried non-steroidal anti-inflammatory drugs (NSAIDs), but they have not worked.
NICE has developed a medtech innovation briefing (MIB) on digital technologies for the detection of melanoma .
disease severity and impact:- In children, young people and adults with psoriasis, can tools be developed and/or existing ones further...
NICE approves first treatment in pilot of new approach to cost-comparison fast track appraisals
As part of the recovery from the COVID-19 pandemic, NICE has been working hard to find new ways to develop and publish guidance affected by the work programme pause in 2020, while also delivering the planned programme for 2021.